Kiniksa Pharmaceuticals International, plc KNSA Accrued Collaboration Expenses Current
Accrued Collaboration Expenses Current at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept knsa:AccruedCollaborationExpensesCurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's accrued collaboration expenses current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's accrued collaboration expenses current?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported accrued collaboration expenses current of $75.58M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's accrued collaboration expenses current changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's accrued collaboration expenses current increased by 40.5% year-over-year, from $53.78M to $75.58M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's accrued collaboration expenses current?
- Over 2 years (2023 to 2025), Kiniksa Pharmaceuticals International, plc's accrued collaboration expenses current has grown at a 103.3% compound annual growth rate (CAGR), from $16.94M to $70.02M.
- What does accrued collaboration expenses current mean?
- This metric represents the current portion of liabilities arising from ongoing research, development, or commercialization partnerships with other entities. It reflects obligations for shared costs, milestone payments, or other contractual commitments due within the next twelve months. Monitoring this balance provides insight into the company's near-term financial commitments related to its strategic collaborative pipeline.